294
Participants
Start Date
October 20, 2025
Primary Completion Date
January 29, 2030
Study Completion Date
January 28, 2033
PF-08052667
PF-08052667 will be administered intravesical (IVe) instillation following a PF-02921367 (DDM) bladder pre-wash
Sasanlimab
Sasanlimab will be administered as subcutaneous (SC) injection
BCG
BCG will be administered intravesical (IVe) instillation
PF-02921367
PF-02921367 (DDM) is a 10-min pre- wash and will be administered intravesical (IVe) instillation
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
Upstate Specialty Services at Harrison Center, Syracuse
SUNY Upstate Medical University, Syracuse
SUNY Upstate Medical University-Community Campus, Syracuse
Ospedale San Raffaele, Milan
Hospital Universitario 12 de Octubre, Madrid
Carolina Urologic Research Center, LLC, Myrtle Beach
Emory University School of Medicine, Atlanta
Emory University, Atlanta
AdventHealth Orlando, Orlando
Moffitt Cancer Center, Tampa
University of Alabama at Birmingham, Birmingham
Urology Associates, P.C., Nashville
University of Iowa, Iowa City
Northwestern University, Evanston
University of Kansas Medical Center, Kansas City
The University of Kansas - Clinical Research Center, Fairway
Pitie Salpetriere University Hospital, Paris
UT Southwestern Medical Center-William P. Clements Imaging Center, Dallas
UT Southwestern Medical Center, Dallas
Houston Methodist Hospital, Houston
Baptist M&S Imaging (Medical Center), San Antonio
USA Clinical Trials, San Antonio
MCOA Eye Associates, San Antonio
Gustave Roussy, Villejuif
Rambam Health Care Campus, Haifa
Rabin Medical Center, Petah Tikva
Sheba Medical Center, Ramat Gan
Hadassah Medical Center, Jerusalem
Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Fundació Puigvert, Barcelona
St Bartholomew's Hospital, London
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield
Lead Sponsor
Pfizer
INDUSTRY